Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ReoPro (Abciximab) Complements Primary Stenting In Acute Myocardial Infarction MALVERN, PA -- May 29, 2000 -- New data from the ADMIRAL study released at the Paris Course on Revascularization suggest significantly better clinical outcomes for patients undergoing primary stenting in acute myocardial infarction (AMI) when treated with abciximab. The trial, which focused on patients with AMI, found that patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and primary coronary stent implantation who were treated with abciximab appeared to have: -- a reduced risk of death: mortality at six months being 3.3 percent in the abciximab group compared with 7.3 percent in the placebo group (i.e.; stenting without abciximab treatment) -- improved coronary artery patency -- improved procedural success of primary stenting -- improvement in long-term TIMI 3 flow rate -- improvement of global left ventricular function at 24 hours and at six months that can be associated directly with abciximab due to all patients undergoing stenting. "The six month data from the ADMIRAL trial clearly seems to show that abciximab improves clinical outcomes for AMI patients undergoing PTCA and stent placement," said Professor Giles Montalescot, Hopital Pitie Salpetriere, Paris, France, who presented the results at the Paris Course on Revascularization. The ADMIRAL (Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up) study is a double-blind, placebo controlled, multi-center trial of 300 AMI patients undertaken in 28 centers across France. The aim of the study was to determine if stenting plus abciximab during PTCA had superior outcome to PTCA and stenting alone. The primary endpoint of the study was the composite incidence of death from any cause , nonfatal reinfarction or urgent target vessel revascularization in the first 30 days with evaluation of clinical outcomes, angiographic coronary patency and left ventricular function at both 24 hours and six months. The most common side effect of ReoPro is bleeding at the site of catheter insertion. However, bleeding events can be reduced to a level similar to placebo by the use of low-dose, weight-adjusted heparin regimens, early sheath removal, and meticulous care of the site of catheter insertion. Abciximab (ReoPro®) is marketed in Europe by Eli Lilly and Company and was developed by Centocor, Inc., Malvern, Pa. ReoPro is jointly marketed in the United States by Eli Lilly and Company and Centocor, Inc. Eli Lilly and Company distributes the product worldwide, except in Japan, where Fujisawa Pharmaceutical Co., Ltd. will distribute it upon approval. The drug was developed by Centocor of Malvern, Pa., and is manufactured by Centocor B.V. in Leiden, the Netherlands. Centocor is a leading biopharmaceutical company that creates , acquires and markets cost-effective therapies that yield long-term benefits for patients and the healthcare community. Its products, developed through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life. Centocor is a wholly owned subsidiary of Johnson & Johnson the worldwide manufacturer of healthcare products. Eli Lilly and Company is a global research-based pharmaceutical corporation headquartered in Indianapolis, Ind., dedicated to creating and delivering innovative pharmaceutical-based healthcare solutions that enable people to live longer, healthier and more active lives. Related Links: Abciximab (ReoPro), Centocor, Inc. and Eli Lilly and Company. E-mail this page to a friend or colleague! To print, use this version